Teriflunomide-induced Raynaud's phenomenon: a serious adverse event, previously unreported.

1 A, B After teriflunomide reintroduction, the patient experimented a marked Raynaud's phenomenon (RP) consisting in: (i) digital colour changes, (ii) finger swallowing and (iii) painful digital sores. Keywords: Multiple sclerosis; Raynaud; Teriflunomide EN Multiple sclerosis Raynaud Teriflunomide 6593 6594 2 10/31/22 20221101 NES 221101 To the Editor, Teriflunomide, sold under the brand name Aubagio®, is an immunomodulatory drug inhibiting pyrimidine de novo synthesis by blocking the enzyme dihydroorotate dehydrogenase. It has been approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of patients with remitting relapsing multiple sclerosis (rrMS) [[1]]. [Extracted from the article]

Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)